These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

398 related articles for article (PubMed ID: 22074425)

  • 1. Prodrugs for targeted tumor therapies: recent developments in ADEPT, GDEPT and PMT.
    Tietze LF; Schmuck K
    Curr Pharm Des; 2011; 17(32):3527-47. PubMed ID: 22074425
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Novel analogues of CC-1065 and the duocarmycins for the use in targeted tumour therapies.
    Tietze LF; Krewer B
    Anticancer Agents Med Chem; 2009 Mar; 9(3):304-25. PubMed ID: 19275523
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antibody-directed enzyme prodrug therapy: a promising approach for a selective treatment of cancer based on prodrugs and monoclonal antibodies.
    Tietze LF; Krewer B
    Chem Biol Drug Des; 2009 Sep; 74(3):205-11. PubMed ID: 19660031
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prodrugs in cancer chemotherapy.
    Connors TA; Knox RJ
    Stem Cells; 1995 Sep; 13(5):501-11. PubMed ID: 8528099
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Synthesis and biological evaluation of prodrugs based on the natural antibiotic duocarmycin for use in ADEPT and PMT.
    Tietze LF; Schmuck K; Schuster HJ; Müller M; Schuberth I
    Chemistry; 2011 Feb; 17(6):1922-9. PubMed ID: 21274943
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antibody directed enzyme prodrug therapy (ADEPT) and related approaches for anticancer therapy.
    Jung M
    Mini Rev Med Chem; 2001 Nov; 1(4):399-407. PubMed ID: 12369965
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The choice of prodrugs for gene directed enzyme prodrug therapy of cancer.
    Connors TA
    Gene Ther; 1995 Dec; 2(10):702-9. PubMed ID: 8750009
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Selective activation of anthracycline prodrugs for use in conjunction with ADEPT.
    HariKrishna D; Rao AR; Krishna DR
    Drug News Perspect; 2003 Jun; 16(5):309-18. PubMed ID: 12942162
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prodrugs for antibody- and gene-directed enzyme prodrug therapies (ADEPT and GDEPT).
    Niculescu-Duvaz I; Friedlos F; Niculescu-Duvaz D; Davies L; Springer CJ
    Anticancer Drug Des; 1999 Dec; 14(6):517-38. PubMed ID: 10834273
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Selective activation of anticancer prodrugs by monoclonal antibody-enzyme conjugates.
    Wallace PM; Senter PD
    Methods Find Exp Clin Pharmacol; 1994 Sep; 16(7):505-12. PubMed ID: 7885077
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prodrugs: a challenge for the drug development.
    Zawilska JB; Wojcieszak J; Olejniczak AB
    Pharmacol Rep; 2013; 65(1):1-14. PubMed ID: 23563019
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Strategies for enzyme/prodrug cancer therapy.
    Xu G; McLeod HL
    Clin Cancer Res; 2001 Nov; 7(11):3314-24. PubMed ID: 11705842
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cytochrome P450 gene-directed enzyme prodrug therapy (GDEPT) for cancer.
    Chen L; Waxman DJ
    Curr Pharm Des; 2002; 8(15):1405-16. PubMed ID: 12052216
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Viral vectors for gene-directed enzyme prodrug therapy.
    Schepelmann S; Springer CJ
    Curr Gene Ther; 2006 Dec; 6(6):647-70. PubMed ID: 17168697
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Beta-glucuronidase-mediated drug release.
    de Graaf M; Boven E; Scheeren HW; Haisma HJ; Pinedo HM
    Curr Pharm Des; 2002; 8(15):1391-403. PubMed ID: 12052215
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The design of selectively-activated anti-cancer prodrugs for use in antibody-directed and gene-directed enzyme-prodrug therapies.
    Denny WA; Wilson WR
    J Pharm Pharmacol; 1998 Apr; 50(4):387-94. PubMed ID: 9625483
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeted enzyme prodrug therapies.
    Schellmann N; Deckert PM; Bachran D; Fuchs H; Bachran C
    Mini Rev Med Chem; 2010 Sep; 10(10):887-904. PubMed ID: 20560876
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Status Quo in Antibody-Drug Conjugates - Can Glyco- Enzymes Solve the Current Challenges?
    Kubizek F; Eggenreich B; Spadiut O
    Protein Pept Lett; 2017; 24(8):686-695. PubMed ID: 28741467
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prodrug cancer gene therapy.
    Altaner C
    Cancer Lett; 2008 Nov; 270(2):191-201. PubMed ID: 18502571
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Gene directed enzyme prodrug therapy for ovarian cancer: could GDEPT become a promising treatment against ovarian cancer?
    Nawa A; Tanino T; Luo C; Iwaki M; Kajiyama H; Shibata K; Yamamoto E; Ino K; Nishiyama Y; Kikkawa F
    Anticancer Agents Med Chem; 2008 Feb; 8(2):232-9. PubMed ID: 18288924
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.